The possibilities of increasing the effectiveness of patients with chronic brain ischemia against the background of Covid-19

Authors:
V.V. KOVALCHUK, I.I. ERSHOVA, N.V. MOLODOVSKAYA

St. Petersburg GBUZ "City Hospital No. 38 named after N.A. Semashko ", St. Petersburg, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 3, Issue 2

Abstract:
Objective of the study. To study the possibility of increasing the effectiveness of treatment of patients with chronic cerebral ischemia (CCI) against the background of COVID-19 using Mexidol. Material and methods. A total of 304 patients with CCI and COVID-19 were observed; Group 1 (n=152) consisted of patients who received basic therapy and Mexidol, Group 2 (n=152) — those who received only basic therapy. Mexidol was administered intravenously by drip at 500 mg (10 ml) per 400 ml of saline solution for 14 days, then Mexidol FORTE 250 was prescribed at 250 mg 3 times a day for 2 months. The state of cognitive functions (MoCA scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), quality of life (SIP questionnaire) were assessed. The examination was conducted before treatment and 30 and 75 days after its initiation. Results. Patients in Group 1 demonstrated: more complete and earlier recovery of cognitive functions (increase in MoCA scores, p < 0.05) . Conclusion. Long-term sequential therapy with Mexidol ensures more complete recovery of impaired functions in patients with chronic cerebral ischemia and COVID-19. Keywords: COVID-19, SARS-CoV-2 virus, chronic cerebral ischemia, asthenia, cognitive impairment, dementia, quality of life, Mexidol.